Intra-Cellular Therapies (ITCI) shares rallied 9.6% in the last trading session to close at $75.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.4% gain over the past four weeks. The sudden soaring of the stock price was observed after the company announced achieving statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of the second late-stage st ...